Oladapo Olumoroti Yeku, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
CA-125 Antigen | 4 | 2024 | 286 | 1.300 |
Why?
|
Immunotherapy, Adoptive | 5 | 2023 | 1271 | 1.170 |
Why?
|
Ovarian Neoplasms | 10 | 2024 | 4839 | 1.150 |
Why?
|
Antigen-Antibody Reactions | 1 | 2024 | 363 | 0.940 |
Why?
|
Membrane Proteins | 4 | 2024 | 7882 | 0.840 |
Why?
|
T-Lymphocytes | 6 | 2023 | 10183 | 0.710 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 2540 | 0.710 |
Why?
|
Genetic Counseling | 1 | 2023 | 600 | 0.710 |
Why?
|
Acidosis, Lactic | 1 | 2021 | 142 | 0.700 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 426 | 0.690 |
Why?
|
Antibodies, Bispecific | 1 | 2021 | 164 | 0.660 |
Why?
|
Endometrial Neoplasms | 3 | 2022 | 1351 | 0.640 |
Why?
|
Vulvar Neoplasms | 1 | 2020 | 272 | 0.620 |
Why?
|
DNA, Complementary | 2 | 2011 | 2050 | 0.550 |
Why?
|
Neuroblastoma | 1 | 2023 | 1226 | 0.510 |
Why?
|
Radium | 1 | 2015 | 65 | 0.490 |
Why?
|
Metformin | 1 | 2021 | 836 | 0.470 |
Why?
|
Brachytherapy | 1 | 2022 | 1248 | 0.470 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1524 | 0.430 |
Why?
|
Tumor Microenvironment | 6 | 2020 | 3590 | 0.390 |
Why?
|
Hypoglycemic Agents | 1 | 2021 | 2873 | 0.330 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1968 | 0.320 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2011 | 323 | 0.320 |
Why?
|
Cell Line, Tumor | 7 | 2023 | 16690 | 0.320 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3154 | 0.320 |
Why?
|
Ascites | 3 | 2020 | 344 | 0.310 |
Why?
|
Immunotherapy | 3 | 2020 | 4446 | 0.310 |
Why?
|
Inflammation Mediators | 1 | 2016 | 1888 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4034 | 0.250 |
Why?
|
Alternative Splicing | 1 | 2009 | 1117 | 0.230 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6773 | 0.220 |
Why?
|
Bone Neoplasms | 1 | 2015 | 2530 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13693 | 0.210 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2021 | 3554 | 0.210 |
Why?
|
Oncogene Proteins, Viral | 1 | 2023 | 362 | 0.190 |
Why?
|
Cytokines | 1 | 2016 | 7323 | 0.190 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 307 | 0.180 |
Why?
|
Macrophages, Peritoneal | 1 | 2020 | 251 | 0.180 |
Why?
|
Drug Synergism | 2 | 2021 | 1794 | 0.170 |
Why?
|
Fluorescence | 1 | 2022 | 751 | 0.170 |
Why?
|
Phospholipase D | 2 | 2010 | 70 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 11525 | 0.160 |
Why?
|
Fluorouracil | 1 | 2023 | 1619 | 0.160 |
Why?
|
Nausea | 1 | 2021 | 674 | 0.160 |
Why?
|
Galectins | 1 | 2021 | 268 | 0.160 |
Why?
|
Genital Neoplasms, Female | 1 | 2023 | 523 | 0.160 |
Why?
|
Single-Chain Antibodies | 1 | 2018 | 108 | 0.160 |
Why?
|
Tumor Escape | 1 | 2020 | 350 | 0.150 |
Why?
|
Ligands | 3 | 2022 | 3282 | 0.150 |
Why?
|
RNA, Messenger | 2 | 2011 | 13035 | 0.150 |
Why?
|
Humans | 26 | 2024 | 744366 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 299 | 0.140 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9274 | 0.140 |
Why?
|
Vagina | 1 | 2022 | 825 | 0.140 |
Why?
|
Blood Proteins | 1 | 2021 | 1124 | 0.130 |
Why?
|
Female | 15 | 2024 | 380193 | 0.130 |
Why?
|
Creatinine | 1 | 2021 | 1919 | 0.130 |
Why?
|
Neoplasms | 3 | 2023 | 21696 | 0.130 |
Why?
|
Interleukin-12 | 1 | 2017 | 580 | 0.130 |
Why?
|
Peritoneal Neoplasms | 1 | 2020 | 665 | 0.120 |
Why?
|
DNA Repair | 1 | 2024 | 2046 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1662 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1348 | 0.120 |
Why?
|
Transforming Growth Factor alpha | 1 | 2014 | 135 | 0.120 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 149 | 0.110 |
Why?
|
Radioisotopes | 1 | 2015 | 500 | 0.110 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11126 | 0.110 |
Why?
|
Stromal Cells | 1 | 2019 | 1355 | 0.110 |
Why?
|
Immune System | 1 | 2018 | 806 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 357 | 0.100 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1862 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2023 | 1587 | 0.100 |
Why?
|
Referral and Consultation | 1 | 2023 | 3531 | 0.090 |
Why?
|
Lymph Nodes | 1 | 2022 | 3476 | 0.090 |
Why?
|
Mice | 9 | 2021 | 81201 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3511 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 9240 | 0.090 |
Why?
|
Disease Models, Animal | 4 | 2021 | 18034 | 0.090 |
Why?
|
Domperidone | 1 | 2008 | 23 | 0.080 |
Why?
|
Animals | 11 | 2021 | 168768 | 0.080 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2011 | 437 | 0.080 |
Why?
|
DNA-Binding Proteins | 2 | 2023 | 9647 | 0.080 |
Why?
|
Oligonucleotides | 1 | 2011 | 572 | 0.080 |
Why?
|
DNA Primers | 1 | 2011 | 2891 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12961 | 0.070 |
Why?
|
Chemotaxis | 1 | 2008 | 607 | 0.070 |
Why?
|
Rad51 Recombinase | 1 | 2024 | 189 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 2938 | 0.060 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2023 | 123 | 0.060 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 21833 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 68 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 88 | 0.050 |
Why?
|
HLA-A Antigens | 1 | 2023 | 232 | 0.050 |
Why?
|
Aged | 4 | 2022 | 163288 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2014 | 3778 | 0.050 |
Why?
|
Autophagy | 1 | 2010 | 1297 | 0.050 |
Why?
|
Cells, Cultured | 1 | 2017 | 19233 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 6486 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4751 | 0.050 |
Why?
|
Apoptosis | 1 | 2017 | 9724 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2023 | 262 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2022 | 63107 | 0.050 |
Why?
|
Survival Rate | 1 | 2015 | 12788 | 0.050 |
Why?
|
Carboplatin | 1 | 2023 | 801 | 0.050 |
Why?
|
Phthalazines | 1 | 2022 | 363 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9955 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2024 | 594 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2020 | 278 | 0.040 |
Why?
|
Spheroids, Cellular | 1 | 2020 | 351 | 0.040 |
Why?
|
Glucose | 1 | 2011 | 4398 | 0.040 |
Why?
|
Phosphorylation | 1 | 2009 | 8436 | 0.040 |
Why?
|
Cricetulus | 2 | 2010 | 818 | 0.040 |
Why?
|
Autocrine Communication | 1 | 2018 | 171 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 11726 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2024 | 1149 | 0.040 |
Why?
|
Heart Failure | 1 | 2021 | 10895 | 0.040 |
Why?
|
Microscopy, Electron | 2 | 2011 | 2646 | 0.040 |
Why?
|
Interleukin-18 | 1 | 2018 | 249 | 0.040 |
Why?
|
Cell Movement | 1 | 2008 | 5218 | 0.040 |
Why?
|
CHO Cells | 2 | 2010 | 1409 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2021 | 1656 | 0.030 |
Why?
|
Insulin | 1 | 2011 | 6582 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1837 | 0.030 |
Why?
|
Cricetinae | 2 | 2010 | 2475 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2020 | 14561 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5511 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2022 | 20824 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2190 | 0.030 |
Why?
|
Mice, Nude | 1 | 2021 | 3689 | 0.030 |
Why?
|
Indoles | 1 | 2022 | 1839 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8432 | 0.030 |
Why?
|
Quality of Life | 1 | 2015 | 12802 | 0.030 |
Why?
|
Prognosis | 3 | 2020 | 29060 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2022 | 77460 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2716 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2417 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2019 | 1403 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2019 | 1741 | 0.020 |
Why?
|
Middle Aged | 2 | 2022 | 213390 | 0.020 |
Why?
|
Collagen | 1 | 2019 | 2688 | 0.020 |
Why?
|
Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 17 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3646 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7294 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2725 | 0.020 |
Why?
|
Male | 3 | 2016 | 350115 | 0.020 |
Why?
|
Obesity | 1 | 2011 | 12746 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2019 | 2638 | 0.020 |
Why?
|
HL-60 Cells | 1 | 2008 | 365 | 0.020 |
Why?
|
Androstadienes | 1 | 2010 | 345 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5882 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2011 | 1151 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2008 | 677 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2019 | 3589 | 0.020 |
Why?
|
Cytoskeleton | 1 | 2011 | 1185 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2505 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2018 | 4666 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1085 | 0.020 |
Why?
|
Islets of Langerhans | 1 | 2011 | 1352 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11031 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13286 | 0.010 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 1970 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12207 | 0.010 |
Why?
|
HeLa Cells | 1 | 2010 | 3130 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6896 | 0.010 |
Why?
|
Actins | 1 | 2011 | 2121 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6539 | 0.010 |
Why?
|
MicroRNAs | 1 | 2019 | 3751 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2018 | 10483 | 0.010 |
Why?
|
Blotting, Western | 1 | 2010 | 5181 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23404 | 0.010 |
Why?
|
tau Proteins | 1 | 2010 | 1868 | 0.010 |
Why?
|
Homeostasis | 1 | 2011 | 3339 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12356 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2010 | 2917 | 0.010 |
Why?
|
Mutation | 1 | 2023 | 29786 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 3799 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2011 | 11366 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5692 | 0.010 |
Why?
|
Diet | 1 | 2011 | 7937 | 0.010 |
Why?
|
Risk Factors | 1 | 2014 | 72296 | 0.000 |
Why?
|
Adult | 1 | 2020 | 214052 | 0.000 |
Why?
|